Kyle TK, Dhurandhar EJ, Allison DB. Regarding Obesity as a Disease: Evolving Policies and Their Implications. Endocrinol Metab Clin North Am. 2016;45(3):511–20.

Article  PubMed  PubMed Central  Google Scholar 

Collaboration NCDRF. Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024;403(10431):1027–50.

Article  Google Scholar 

Collaborators GBDRF. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1223–49.

Article  Google Scholar 

Economic impact of overweight and obesity to surpass $4 trillion by 2035. In: The World Obesity Atlas. World Obesity Federation. 2023. https://www.worldobesity.org/news/economic-impact-of-overweight-and-obesity-to-surpass-4-trillion-by-2035. Accessed 12 May 2024.

Fruhbeck G, Busetto L, Dicker D, Yumuk V, Goossens GH, Hebebrand J, et al. The ABCD of Obesity: An EASO Position Statement on a Diagnostic Term with Clinical and Scientific Implications. Obes Facts. 2019;12(2):131–6.

Article  PubMed  PubMed Central  Google Scholar 

Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023;148(20):1606–35.

Article  PubMed  Google Scholar 

Ryan DH, Yockey SR. Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over. Curr Obes Rep. 2017;6(2):187–94.

Article  PubMed  PubMed Central  Google Scholar 

Hartmann-Boyce J, Cobiac LJ, Theodoulou A, Oke JL, Butler AR, Scarborough P, et al. Weight regain after behavioural weight management programmes and its impact on quality of life and cost effectiveness: Evidence synthesis and health economic analyses. Diabetes Obes Metab. 2023;25(2):526–35.

Article  PubMed  Google Scholar 

Comerma-Steffensen S, Grann M, Andersen CU, Rungby J, Simonsen U. Cardiovascular effects of current and future anti-obesity drugs. Curr Vasc Pharmacol. 2014;12(3):493–504.

Article  CAS  PubMed  Google Scholar 

Muller TD, Bluher M, Tschop MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21(3):201–23.

Article  PubMed  Google Scholar 

Bray GA, Purnell JQ, et al. An historical review of steps and missteps in the discovery of anti-obesity drugs. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, et al. (eds.), Endotext. South Dartmouth; 2000.

Kraus WE, Bhapkar M, Huffman KM, Pieper CF, Krupa Das S, Redman LM, et al. 2 years of calorie restriction and cardiometabolic risk (CALERIE): exploratory outcomes of a multicentre, phase 2, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(9):673–83.

Article  PubMed  PubMed Central  Google Scholar 

Salas-Salvado J, Diaz-Lopez A, Ruiz-Canela M, Basora J, Fito M, Corella D, et al. Effect of a Lifestyle Intervention Program With Energy-Restricted Mediterranean Diet and Exercise on Weight Loss and Cardiovascular Risk Factors: One-Year Results of the PREDIMED-Plus Trial. Diabetes Care. 2019;42(5):777–88.

Article  CAS  PubMed  Google Scholar 

Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(25 Suppl 2):S102–38.

PubMed  Google Scholar 

Look ARG, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145–54.

Article  Google Scholar 

Look ARG. Effects of Intensive Lifestyle Intervention on All-Cause Mortality in Older Adults With Type 2 Diabetes and Overweight/Obesity: Results From the Look AHEAD Study. Diabetes Care. 2022;45(5):1252–9.

Article  Google Scholar 

Polidori D, Sanghvi A, Seeley RJ, Hall KD. How Strongly Does Appetite Counter Weight Loss? Quantification of the Feedback Control of Human Energy Intake. Obesity (Silver Spring). 2016;24(11):2289–95.

Article  CAS  PubMed  Google Scholar 

Klem ML, Wing RR, McGuire MT, Seagle HM, Hill JO. A descriptive study of individuals successful at long-term maintenance of substantial weight loss. Am J Clin Nutr. 1997;66(2):239–46.

Article  CAS  PubMed  Google Scholar 

Phelan S, Halfman T, Pinto AM, Foster GD. Behavioral and Psychological Strategies of Long-Term Weight Loss Maintainers in a Widely Available Weight Management Program. Obesity (Silver Spring). 2020;28(2):421–8.

Article  PubMed  Google Scholar 

Varkevisser RDM, van Stralen MM, Kroeze W, Ket JCF, Steenhuis IHM. Determinants of weight loss maintenance: a systematic review. Obes Rev. 2019;20(2):171–211.

Article  CAS  PubMed  Google Scholar 

FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market. U.S. Food & Drug Administration. 2020. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-withdrawal-weight-loss-drug-belviq-belviq-xr-lorcaserin-market. Accessed 12 May 2024.

Perdomo CM, Cohen RV, Sumithran P, Clement K, Fruhbeck G. Contemporary medical, device, and surgical therapies for obesity in adults. Lancet. 2023;401(10382):1116–30.

Article  PubMed  Google Scholar 

Tchang BG, Aras M, Kumar RB, Aronne LJ, et al. Pharmacologic treatment of overweight and obesity in adults. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, et al. (eds.), Endotext. South Dartmouth; 2000.

MacEwan J, Kan H, Chiu K, Poon JL, Shinde S, Ahmad NN. Antiobesity Medication Use Among Overweight and Obese Adults in the United States: 2015–2018. Endocr Pract. 2021;27(11):1139–48.

Article  PubMed  Google Scholar 

Eisenberg D, Shikora SA, Aarts E, Aminian A, Angrisani L, Cohen RV, et al. 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for Metabolic and Bariatric Surgery. Surg Obes Relat Dis. 2022;18(12):1345–56.

Article  PubMed  Google Scholar 

Doumouras AG, Wong JA, Paterson JM, Lee Y, Sivapathasundaram B, Tarride JE, et al. Bariatric Surgery and Cardiovascular Outcomes in Patients With Obesity and Cardiovascular Disease: A Population-Based Retrospective Cohort Study. Circulation. 2021;143(15):1468–80.

Article  CAS  PubMed  Google Scholar 

Gasoyan H, Tajeu G, Halpern MT, Sarwer DB. Reasons for underutilization of bariatric surgery: The role of insurance benefit design. Surg Obes Relat Dis. 2019;15(1):146–51.

Article  PubMed  Google Scholar 

Nauck MA, Meier JJ. Incretin hormones: Their role in health and disease. Diabetes Obes Metab. 2018;20(Suppl 1):5–21.

Article  CAS  PubMed  Google Scholar 

Abushamat LA, Shah PA, Eckel RH, Harrison SA, Barb D. The emerging role of glucagon-like peptide-1 receptor agonists for the treatment of metabolic dysfunction-associated steatohepatitis. Clin Gastroenterol Hepatol. 2024; S1542–3565(24)00160–5.

Wu AY, Peebles RS. The GLP-1 receptor in airway inflammation in asthma: a promising novel target? Expert Rev Clin Immunol. 2021;17(10):1053–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao C, Liang J, Yang Y, Yu M, Qu X. The Impact of Glucagon-Like Peptide-1 on Bone Metabolism and Its Possible Mechanisms. Front Endocrinol (Lausanne). 2017;8:98.

Article  PubMed  Google Scholar 

Wang N, Tan AWK, Jahn LA, Hartline L, Patrie JT, Lin S, et al. Vasodilatory Actions of Glucagon-Like Peptide 1 Are Preserved in Skeletal and Cardiac Muscle Microvasculature but Not in Conduit Artery in Obese Humans With Vascular Insulin Resistance. Diabetes Care. 2020;43(3):634–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Villumsen M, Schelde AB, Jimenez-Solem E, Jess T, Allin KH. GLP-1 based therapies and disease course of inflammatory bowel disease. EClinicalMedicine. 2021;37:100979.

Article  PubMed  PubMed Central  Google Scholar 

Neha, Wali Z, Pinky, Hattiwale SH, Jamal A, Parvez S. GLP-1/Sigma/RAGE receptors: An evolving picture of Alzheimer’s disease pathology and treatment. Ageing Res Rev. 2024;93:102134.

Article  CAS  PubMed  Google Scholar 

Klausen MK, Thomsen M, Wortwein G, Fink-Jensen A. The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. Br J Pharmacol. 2022;179(4):625–41.

Article  PubMed  Google Scholar 

Kanoski SE, Fortin SM, Arnold M, Grill HJ, Hayes MR. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology. 2011;152(8):3103–12.

Article  CAS  PubMed